⌘+K

Equity Story

Near term

6-12 MONTHS

Alzinova is actively engaged in partnership discussions concerning a potential licensing agreement for ALZ-101. In our view, this represents the most important potential near-term catalyst for the story.

Long term

6+ YEARS

The long-term story for Alzinova centres on ALZ-101 demonstrating encouraging clinical data and eventually achieving market approval. The high prevalence of Alzheimer’s disease, combined with the substantial healthcare costs it entails, creates considerable market potential for disease-modifying therapies. GlobalData expects the Alzheimer’s treatment market to expand at a 23.4% CAGR through 2033.

Key risks

  • Early-stage clinical development companies face significant risks, including failure in planned studies, regulatory hurdles, and uncertainty regarding study timing and results. Such risks are generally high at this stage of development.

  • Alzheimer’s disease clinical trials require lengthy follow-up periods, posing recruitment and timing risks.

  • The company is likely to need more capital before reaching breakeven.

Fair value range

Price

Fair range high value

Fair range low value

The lower end of our fair value range is derived from our SOTP model using a DCF with a WACC of 22%, reflecting a scenario where the company delivers on our expectations but broader sentiment towards biotech remains subdued. The upper end, based on a WACC of 18%, assumes the same operational performance but with improving sector sentiment. We apply a relatively high WACC to capture the financing risk overhang, as the company will likely need to raise additional capital to initiate its Phase II trial should a partnership agreement not materialise.

Valuation and methodology

We use a sum-of-the-parts approach in our valuation of Alzinova, with different DCFs for the upper end and lower end of the fair value range. In our model, we project peak sales of USD3.2bn for ALZ-101 in Alzheimer's disease. We assign the project a 12% likelihood of approval (LoA). Due to the absence of completed clinical trials, we have not yet included ALZ-201 in our valuation model.

Key metrics

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB